A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Condition:   SmallpoxInterventions:   Biological: IMVAMUNE;   Biological: IMVAMUNE;   Biological: IMVAMUNE;   Other: PlaceboSponsor:   Bavarian NordicCompleted - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials